Q-Line Biotech IPO Listing gains
| Listing Date | May 29, 2026 |
| NSE Code | QLINE |
| ISIN Code | INE1G2W01011 |
| Offer Price | ₹326 to ₹343 |
| Face Value | ₹10 |
| Listing Price | ₹452 |
Details About Q-Line Biotech IPO
Q-Line Biotech got approval from SEBI for an IPO of around ₹214.48 crores, via fresh issues. Further, Q-Line Biotech had a price band of ₹326 to ₹343 per share.
In the Q-Line Biotech IPO, 800 shares were offered in 2 lot sizes for the retail minimum and maximum categories as well. 1200 shares were in 3 lot sizes for the S-HNI Minimum category. S-HNI maximum has 2800 shares in 7 lot sizes. B-HNI has 3200 shares in 8 lot sizes.
To invest in the Q-Line Biotech IPO, each investor category has specific investment amounts:
- Retail Investors: Minimum and maximum investment of ₹2,74,400.
- S-HNI (Min): Minimum investment of ₹4,11,600.
- S-HNI Maximum: investment of ₹9,60,400.
- B-HNI Minimum: investment of ₹10,97,600.
Q-Line Biotech IPO’s Subscription Duration
The opening date of Q-Line Biotech IPO was on May 21, 2026, and the closing date was on May 25, 2026. The allotment date of the Q-Line Biotech IPO was on May 26, 2026, and the investors will receive a refund on May 27, 2026. Q-Line Biotech is set to be listed on May 29, 2026.
Funds Deployment of This Company
- The funds raised from the fresh issue will be used towards the working capital requirements.
- Some funds will be used towards the repayment of existing borrowings taken by the company.
- Lastly, the remaining will go towards the General Corporate Purpose.
About Q-Line Biotech Company
Q-Line Biotech, founded in 2013, is one of the growing healthcare and diagnostic companies, involved in the manufacturing and supplying of In-Vitro Diagnostic (IVD) products and other healthcare products such as medical diagnostic equipment, reagents, rapid test kits, and pathology instruments. The company also has 12 years of experience in developing and manufacturing various products.
Its product range includes haematology, POC testing, clinical chemistry, molecular diagnostics, rapid tests, ELISA, and special diagnostics. The firm has been known to offer high-quality products and services at an affordable price range. Q-Line Biotech has over 15 years of experience in the diagnostic industry and has served 150+ national and international clients.
Q-Line Biotech IPO Company Financial Report
The company reported revenue of ₹322.58 crores in 2025 against ₹206.45 crores in 2024. The company reported a profit of ₹28.13 crores in 2025 against a profit of ₹34.44 crores in 2024.
